Is ALNY a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Alnylam Pharmaceuticals (ALNY) rests on Amvuttra ATTR-CM ramp: The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch is the single biggest growth driver. Net product revenue (FY2025) is ~$3.0B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. Whether ALNY is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines. Its commercial portfolio includes Amvuttra (vutrisiran) and Onpattro for transthyretin (TTR) amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for a rare kidney disorder, plus royalties on Leqvio, an cholesterol-lowering RNAi drug marketed by partner Novartis. The defining event was the March 2025 FDA approval of Amvuttra for ATTR amyloidosis with cardiomyopathy (ATTR-CM), a far larger patient population than its earlier polyneuropathy indication, based on the HELIOS-B trial showing a 28% reduction in death and cardiac events. That label expansion transformed the financial profile. Full-year 2025 net product revenue reached roughly $3 billion, up about 81%, and the company reached both GAAP and non-GAAP profitability for the first time. Momentum accelerated into 2026, with Q1 net product revenue of about $1.0 billion and net income around $206 million, and management guided full-year 2026 combined net product revenue to roughly $4.9 billion to $5.3 billion. The investment picture is now less about whether the science works and more about how durably Amvuttra can grow the ATTR-CM market against oral competitors, plus what its earlier-stage pipeline (Alzheimer's, bleeding disorders) can add on top.
What's the case for buying ALNY?
1. Amvuttra ATTR-CM ramp
The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch is the single biggest growth driver. As a subcutaneous injection dosed once every three months, it offers a convenience angle versus daily oral therapies. Management's 2026 guidance of roughly $4.9 billion to $5.3 billion in net product revenue is built largely on this ramp continuing.
2. Crossing into sustained profitability
After years of heavy R&D spending, Alnylam reached GAAP and non-GAAP profitability in 2025 and posted roughly $206 million of net income in Q1 2026. This shift means revenue growth increasingly drops through to operating income rather than being consumed by burn. A self-funding commercial engine also reduces the historical risk of dilutive capital raises.
3. RNAi platform and pipeline optionality
Beyond TTR, Alnylam is advancing mivelsiran in Alzheimer's disease, ALN-6400 in a bleeding disorder, and other programs with data readouts expected across the year. Its RNAi delivery technology has already produced multiple approved drugs, giving the platform repeatability that early-stage biotechs lack. Novartis royalties on Leqvio add a growing, lower-risk revenue stream tied to the large cardiovascular market.
4. Global label and geographic expansion
The ATTR-CM indication has secured approvals beyond the US, including the European Commission, Japan, the UK, Brazil, and Canada. Each new geography adds addressable patients to the same commercial franchise without requiring a new drug. This international runway supports the multi-year growth trajectory embedded in analyst expectations.
What are the risks to ALNY?
Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. The ATTR-CM market is now a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. The stock trades at a rich multiple of revenue that assumes years of strong growth, leaving room for sharp drawdowns on any stumble. Drug pricing pressure and patent or regulatory changes are ongoing overhangs for the sector.
How is ALNY valued? (as of JULY 2026)
Snapshot for ALNY as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$42B
- Net product revenue (FY2025): ~$3.0B
- Net product revenue (TTM): ~$3.5B
- 2026 revenue guidance: ~$4.9B to $5.3B
- Q1 2026 net income: ~$206M
- Dividend: None
Alnylam reached profitability in 2025 after nearly $3 billion in net product revenue, and Q1 2026 delivered about $1.0 billion in net product revenue with roughly $206 million of net income. At a market cap near $42 billion against 2026 revenue guidance of roughly $5 billion, the stock carries a premium multiple that prices in continued rapid growth. It pays no dividend and reinvests cash into its RNAi pipeline.
How do you decide if ALNY is a buy?
Rather than asking whether ALNY is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ALNY indirectly through an index or sector ETF before adding more.
For the full picture, see the ALNY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALNY against your real portfolio and see your actual exposure before deciding.
The bottom line on ALNY
The bottom line: Alnylam Pharmaceuticals's story right now is Amvuttra ATTR-CM ramp, with net product revenue (fy2025) at ~$3.0B. If you believe that narrative continues, the call is about sizing ALNY sensibly and checking overlap with what you own; if you doubt it (the risk: revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ALNY with Walnut
Use Alnylam Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ALNY a good stock to buy right now?
+
The case for Alnylam Pharmaceuticals right now is Amvuttra ATTR-CM ramp, with net product revenue (fy2025) at ~$3.0B. If you believe that thesis holds, ALNY is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Alnylam Pharmaceuticals do?
+
Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines.
What are the main risks of ALNY?
+
Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. The ATTR-CM market is now a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. The stock trades at a rich multiple of revenue that assumes years of strong growth, leaving room for sharp drawdowns on any stumble. Drug pricing pressure and patent or regulatory changes are ongoing overhangs for the sector.
What does Alnylam Pharmaceuticals do?
+
Alnylam develops and sells RNA interference (RNAi) therapeutics, medicines that silence disease-causing genes. Its main products treat TTR amyloidosis (Amvuttra and Onpattro), acute hepatic porphyria (Givlaari), and a rare kidney disorder (Oxlumo). It also earns royalties on Leqvio, an RNAi cholesterol drug sold by Novartis. The company pioneered turning the RNAi mechanism into a repeatable drug-development platform.
Why is Amvuttra so important to ALNY?
+
Amvuttra (vutrisiran) is Alnylam's largest revenue driver by a wide margin. Its March 2025 FDA approval for ATTR cardiomyopathy expanded it into a much bigger patient population than its original nerve-disease indication. That single approval is the main reason revenue nearly doubled and the company reached profitability. Because so much revenue rests on it, Amvuttra's performance largely defines the investment case.
Is Alnylam profitable?
+
Yes. After years of heavy research spending, Alnylam reached both GAAP and non-GAAP profitability for full-year 2025 on roughly $3 billion of net product revenue. In Q1 2026 it reported about $206 million of net income on roughly $1.0 billion of net product revenue. Management expects operating income to keep growing as the Amvuttra launch scales.
Does ALNY pay a dividend?
+
No, Alnylam does not pay a dividend. Like most growth-stage biotechs, it reinvests its cash into research, clinical trials, and commercial expansion of its RNAi pipeline. Investors in ALNY are relying entirely on share-price appreciation rather than income. That reflects a company still prioritizing growth over returning capital.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ALNY; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.